When someone has a stroke, their risk of developing pneumonia in the hospital is a serious complication that can slow recovery. A new study looked at whether a simple ratio from a standard blood test—comparing hemoglobin (which carries oxygen) to red blood cell distribution width (a measure of red blood cell size variation)—could signal that risk. The research, which included 1,051 people hospitalized for stroke, found that a lower score on this ratio was associated with a higher chance of getting pneumonia. However, this connection only held true for patients who did not have diabetes; for those with diabetes, the ratio did not show a significant link to pneumonia risk. It's important to remember this study only shows an association—it doesn't prove the blood ratio causes the pneumonia risk. The findings are from looking back at medical records, not from a controlled experiment, so more research is needed to understand if this test could be useful for doctors in planning care.
Lower admission HRR ratio associated with higher stroke-associated pneumonia risk in ischemic strokeCould a simple blood test ratio help predict pneumonia risk after a stroke?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
A retrospective cohort study examined the association between admission hemoglobin-to-red blood cell distribution width ratio (HRR) and stroke-associated pneumonia (SAP) risk in 1051 patients with acute ischemic stroke admitted within 72 hours of symptom onset. The exposure was admission HRR, with no specific comparator reported. The primary outcome was SAP risk.
In the fully adjusted model, HRR showed a linear negative association with SAP risk (adjusted OR=0.75, 95% CI: 0.64-0.87, p<0.001). Stratified analysis revealed a significant interaction with diabetes status (p for interaction=0.01). The inverse association was present in non-diabetic patients (OR=0.69, 95% CI: 0.59-0.81, p<0.001) but not in diabetic patients (OR=0.97, 95% CI: 0.77-1.21, p=0.76). Absolute numbers for SAP incidence were not reported.
Safety and tolerability data were not reported. Key limitations include the observational, retrospective design which cannot establish causality, and generalizability may be limited beyond the studied cohort. The setting and follow-up duration were also not reported.
For practice, this study suggests SAP risk stratification strategies may need to account for diabetes status. However, these findings represent association, not causation, and require prospective validation before influencing clinical decision-making.